The World Diabetes Congress 2022, organized by the International Diabetes Federation (IDF), was successfully held from 5 to 8 December at the Lisbon Convention Centre in Portugal. It provided a unique forum for knowledge exchange, bringing together the extensive global network of physicians, scientists, nurses, educators and other healthcare professionals¹. As an exhibitor, Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH) had academic exchanges and interactions with experts in the field of diabetes around the world and the event was a complete success.

Founded in 1950, the International Diabetes Federation (IDF) is an umbrella organization of over 240 national diabetes associations in 160 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. IDF World Diabetes Congress is held at different sites in the world every other year and the Federation’s activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers².

The programme of the IDF World Diabetes Congress 2022 is organized across eight streams, which are Basic and Translational Science (BTS), Clinical, Therapeutic and Technology Research (CTT), Diabetes Complications and Comorbidities (DCC), Health Services and Policy (HSP), Diabetes in Women (DIW), Education and Integrated Care (EIC), Epidemiology and Public Health (EPH) and Living with Diabetes (LWD)³.

The exhibition activities during the Congress provided a good platform for interaction between exhibitors and experts. Our China and US teams learned that there are urgent needs for safe and effective insulin biosimilar insulins whether in the developed countries or in the emerging markets. Experts are looking forward to the approval of Gan & Lee's insulin drugs in the US and Europe to benefit more diabetic patients. The vice president and COO of Gan & Lee USA, Gary J. Furda said: "This was a very successful event. I’m pleased to share Gan & Lee's efforts in the diabetes community with the experts and we hope more people can be involved in the process of spreading diabetes knowledge. See you next time in Rio de Janeiro.”

Currently Gan & Lee's three biosimilar insulins, glargine, lispro and aspart have completed a number of clinical trials in a few clinical centers in Europe and the US. We are now preparing Investigational New Drug applications (INDs) in the US and Europe. At the same time, Gan & Lee is also actively expanding its product pipeline and is committed to drug development in the fields of cardiovascular disease and oncology. The GLP-1 receptor agonist (GZR18), the fourth-generation ultra-long-acting insulin analogue (GZR4) and the premixed dual insulin (GZR101) independently developed by the company are in simultaneous clinical trials in China and the United States. In the future, we will continue to provide more diversified high-quality products for the patients around the world.

References:

1. IDF Lisbon 2022 website: https://idf2022.org/welcome/

2. IDF official website: https://idf.org/who-we-are.html 

3. Scientific Programme Information from: https://idf2022.org/programme/committee-streams/  

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^?), fast-acting lispro injection (Prandilin^?), fast-acting aspart injection (Rapilin^?), mixed protamine zinc lispro injection (25R) (Prandilin^?25), aspart 30 injection (Rapilin^?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^?).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.